Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to silence chronic cough that Won't quit

NCT ID NCT05599191

Symptom relief Sponsor: Bellus Health Inc. - a GSK company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests an experimental drug called BLU-5937 (camlipixant) in adults with refractory chronic cough, including unexplained chronic cough, that has lasted at least a year. Participants take the drug or a placebo daily for 52 weeks to see if it reduces coughing frequency and severity. The trial also monitors safety, including any taste changes or mouth numbness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental drug called BLU-5937 (camlipixant) taken as a tablet
What this could lead to
If successful, this could provide a new treatment option for people with chronic cough that does not respond to other therapies.
What could go wrong
This is an early Phase 3 trial, so the drug may not prove effective or safe in the long term. Possible side effects include taste disturbances and mouth numbness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

957 people

The number who actually took part.

Started

Oct 2022

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Capable of giving signed informed consent * Refractory chronic cough (including unexplained chronic cough) for at least one year * Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose Exclusion Criteria: * Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history * Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment * Respiratory tract infection within 4 weeks before screening * Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening * History of malignancy in the last 5 years * History of alcohol or drug abuse within the last 3 years * Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus. * Previous participation in a BLU-5937 trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cough are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chronic Cough Cough Respiration Disorders respiratory system disorder Signs and Symptoms, Respiratory

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cough Refractory chronic cough

Contacts and locations

Locations

  • GSK Investigational Site

    Jasper, Alabama, 35501, United States

  • GSK Investigational Site

    Litchfield Park, Arizona, 85340, United States

  • GSK Investigational Site

    Scottsdale, Arizona, 85248, United States

  • GSK Investigational Site

    Little Rock, Arkansas, 72205, United States

  • GSK Investigational Site

    Encinitas, California, 92024, United States

  • GSK Investigational Site

    Mission Viejo, California, 92691, United States

  • GSK Investigational Site

    Paramount, California, 90723, United States

  • GSK Investigational Site

    Roseville, California, 95661, United States

  • GSK Investigational Site

    Aurora, Colorado, 80012, United States

  • GSK Investigational Site

    Colorado Springs, Colorado, 80923, United States

  • GSK Investigational Site

    Clearwater, Florida, 33756, United States

  • GSK Investigational Site

    Gainesville, Florida, 32608, United States

  • GSK Investigational Site

    Miami, Florida, 15801, United States

  • GSK Investigational Site

    Miami, Florida, 33155, United States

  • GSK Investigational Site

    Miami, Florida, 33173, United States

  • GSK Investigational Site

    Miami, Florida, 33186, United States

  • GSK Investigational Site

    Orlando, Florida, 32713, United States

  • GSK Investigational Site

    Lawrenceville, Georgia, 30046, United States

  • GSK Investigational Site

    Normal, Illinois, 61761, United States

  • GSK Investigational Site

    Oak Lawn, Illinois, 60453, United States

  • GSK Investigational Site

    Ames, Iowa, 50010, United States

  • GSK Investigational Site

    Iowa City, Iowa, 52242, United States

  • GSK Investigational Site

    Kansas City, Kansas, 66160, United States

  • GSK Investigational Site

    Topeka, Kansas, 66606, United States

  • GSK Investigational Site

    Wichita, Kansas, 67214, United States

  • GSK Investigational Site

    Crowley, Louisiana, 70526, United States

  • GSK Investigational Site

    Shreveport, Louisiana, 71115, United States

  • GSK Investigational Site

    Annapolis, Maryland, 21404, United States

  • GSK Investigational Site

    North Dartmouth, Massachusetts, 02747, United States

  • GSK Investigational Site

    Ann Arbor, Michigan, 48109, United States

  • GSK Investigational Site

    Ypsilanti, Michigan, 48197, United States

  • GSK Investigational Site

    Columbia, Missouri, 65203, United States

  • GSK Investigational Site

    St Louis, Missouri, 63110, United States

  • GSK Investigational Site

    St Louis, Missouri, 63141, United States

  • GSK Investigational Site

    Missoula, Montana, 59808, United States

  • GSK Investigational Site

    Jersey City, New Jersey, 07304, United States

  • GSK Investigational Site

    The Bronx, New York, 10461, United States

  • GSK Investigational Site

    Charlotte, North Carolina, 28277, United States

  • GSK Investigational Site

    Raleigh, North Carolina, 28401, United States

  • GSK Investigational Site

    Rocky Mount, North Carolina, 27804, United States

  • GSK Investigational Site

    Salisbury, North Carolina, 28144, United States

  • GSK Investigational Site

    Winston-Salem, North Carolina, 27103, United States

  • GSK Investigational Site

    Columbus, Ohio, 43215, United States

  • GSK Investigational Site

    Dayton, Ohio, 45417, United States

  • GSK Investigational Site

    Oklahoma City, Oklahoma, 73104, United States

  • GSK Investigational Site

    Tulsa, Oklahoma, 74136, United States

  • GSK Investigational Site

    Medford, Oregon, 97504, United States

  • GSK Investigational Site

    Portland, Oregon, 97202, United States

  • GSK Investigational Site

    Philadelphia, Pennsylvania, 19140, United States

  • GSK Investigational Site

    Warwick, Rhode Island, 02886, United States

  • GSK Investigational Site

    Charleston, South Carolina, 29406, United States

  • GSK Investigational Site

    Little River, South Carolina, 29566, United States

  • GSK Investigational Site

    Mt. Pleasant, South Carolina, 29464, United States

  • GSK Investigational Site

    Rock Hill, South Carolina, 29732, United States

  • GSK Investigational Site

    Bristol, Tennessee, 37620, United States

  • GSK Investigational Site

    Knoxville, Tennessee, 37938, United States

  • GSK Investigational Site

    Dallas, Texas, 75231-4307, United States

  • GSK Investigational Site

    Houston, Texas, 77074, United States

  • GSK Investigational Site

    Houston, Texas, 77401, United States

  • GSK Investigational Site

    McKinney, Texas, 75069, United States

  • GSK Investigational Site

    San Antonio, Texas, 78229, United States

  • GSK Investigational Site

    Waco, Texas, 76712, United States

  • GSK Investigational Site

    Salt Lake City, Utah, 84132, United States

  • GSK Investigational Site

    Norfolk, Virginia, 23507, United States

  • GSK Investigational Site

    Williamsburg, Virginia, 23188, United States

  • GSK Investigational Site

    Bellevue, Washington, 68123, United States

  • GSK Investigational Site

    Bellingham, Washington, 98225, United States

  • GSK Investigational Site

    Buenos Aires, C1406AGA, Argentina

  • GSK Investigational Site

    Buenos Aires, C199AAB, Argentina

  • GSK Investigational Site

    Ciudad Autonoma Buenos Aires, C1128AAF, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, C1027AAP, Argentina

  • GSK Investigational Site

    Córdoba, X5003DCE, Argentina

  • GSK Investigational Site

    Mar del Plata, B7600FYK, Argentina

  • GSK Investigational Site

    Mendoza, 5500, Argentina

  • GSK Investigational Site

    Rosario, S2000DBS, Argentina

  • GSK Investigational Site

    Rosario, S2000DEJ, Argentina

  • GSK Investigational Site

    Rosario, S2002OJN, Argentina

  • GSK Investigational Site

    San Miguel de Tucumán, T4000IAI, Argentina

  • GSK Investigational Site

    Santa Fe, 3000, Argentina

  • GSK Investigational Site

    Vicente López, 1602, Argentina

  • GSK Investigational Site

    Brussels, 1200, Belgium

  • GSK Investigational Site

    Ghent, 9000, Belgium

  • GSK Investigational Site

    Kortrijk, 8500, Belgium

  • GSK Investigational Site

    Leuven, 3000, Belgium

  • GSK Investigational Site

    Liège, 4000, Belgium

  • GSK Investigational Site

    Mechelen, 2800, Belgium

  • GSK Investigational Site

    Roeselare, 8800, Belgium

  • GSK Investigational Site

    Calgary, Alberta, T2T 5C7, Canada

  • GSK Investigational Site

    Calgary, Alberta, T3E 7M8, Canada

  • GSK Investigational Site

    Kelowna, British Columbia, V1Y3H5, Canada

  • GSK Investigational Site

    Ajax, Ontario, L1S 2J5, Canada

  • GSK Investigational Site

    Hamilton, Ontario, L8M 1K7, Canada

  • GSK Investigational Site

    Hamilton, Ontario, L8N 3Z5, Canada

  • GSK Investigational Site

    Toronto, Ontario, M5T 3A9, Canada

  • GSK Investigational Site

    Windsor, Ontario, N8X 1T3, Canada

  • GSK Investigational Site

    Greenfield Park, Quebec, J4V 2H1, Canada

  • GSK Investigational Site

    Montreal, Quebec, H1M 1B1, Canada

  • GSK Investigational Site

    Montreal, Quebec, H4A 3J1, Canada

  • GSK Investigational Site

    Québec, Quebec, G1N 4V3, Canada

  • GSK Investigational Site

    Québec, Quebec, G1V 4G5, Canada

  • GSK Investigational Site

    Québec, Quebec, G1V 4W2, Canada

  • GSK Investigational Site

    Québec, Quebec, G3K 2P8, Canada

  • GSK Investigational Site

    Saint-Charles-Borromée, Quebec, J6E 2B4, Canada

  • GSK Investigational Site

    Sherbrooke, Quebec, J1H 5N4, Canada

  • GSK Investigational Site

    Trois-Rivières, Quebec, G8T 7A1, Canada

  • GSK Investigational Site

    Victoriaville, Quebec, G6P 6P6, Canada

  • GSK Investigational Site

    Burlington, ON L7N 3V2, Canada

  • GSK Investigational Site

    Floridablanca, 681004, Colombia

  • GSK Investigational Site

    Medellín, 00000, Colombia

  • GSK Investigational Site

    Medellín, 050034, Colombia

  • GSK Investigational Site

    Medellín, 50021, Colombia

  • GSK Investigational Site

    Dijon, 21079, France

  • GSK Investigational Site

    Lille, 59037, France

  • GSK Investigational Site

    Marseille, 13003, France

  • GSK Investigational Site

    Marseille, 13015, France

  • GSK Investigational Site

    Montpellier, 34295, France

  • GSK Investigational Site

    Paris, 75014, France

  • GSK Investigational Site

    Strasbourg, 67091, France

  • GSK Investigational Site

    Toulouse, 31000, France

  • GSK Investigational Site

    Balatonfüred, 8230, Hungary

  • GSK Investigational Site

    Budapest, 1027, Hungary

  • GSK Investigational Site

    Budapest, 1033, Hungary

  • GSK Investigational Site

    Gödöllő, 2100, Hungary

  • GSK Investigational Site

    Hajdúnánás, 4080, Hungary

  • GSK Investigational Site

    Mosonmagyaróvár, 9300, Hungary

  • GSK Investigational Site

    Pécs, 7635, Hungary

  • GSK Investigational Site

    Püspökladány, 4150, Hungary

  • GSK Investigational Site

    Aurangabad, 431003, India

  • GSK Investigational Site

    Bengaluru, 560068, India

  • GSK Investigational Site

    Bikaner, 334001, India

  • GSK Investigational Site

    Delhi, 110076, India

  • GSK Investigational Site

    Jaipur, 302023, India

  • GSK Investigational Site

    Kolkata, 700027, India

  • GSK Investigational Site

    Kozhikode, 673008, India

  • GSK Investigational Site

    Nashik, 422007, India

  • GSK Investigational Site

    Nashik, 422009, India

  • GSK Investigational Site

    Pune, 411004, India

  • GSK Investigational Site

    Rohtak, 124514, India

  • GSK Investigational Site

    Thane, 401107, India

  • GSK Investigational Site

    Ulhasnagar, 421001, India

  • GSK Investigational Site

    Hadera, 169, Israel

  • GSK Investigational Site

    Haifa, 3436212, Israel

  • GSK Investigational Site

    Jerusalem, 9112001, Israel

  • GSK Investigational Site

    Petah Tikva, 4941492, Israel

  • GSK Investigational Site

    Ramat Gan, 52621, Israel

  • GSK Investigational Site

    Tel Aviv, 64239, Israel

  • GSK Investigational Site

    Alkmaar, 1815 JD, Netherlands

  • GSK Investigational Site

    Arnhem, 6815 AD, Netherlands

  • GSK Investigational Site

    Breda, 4818 CK, Netherlands

  • GSK Investigational Site

    Eindhoven, 5623 EJ, Netherlands

  • GSK Investigational Site

    Uden, 5406 PT, Netherlands

  • GSK Investigational Site

    Zutphen, 7207 AE, Netherlands

  • GSK Investigational Site

    Zwolle, 8025 AB, Netherlands

  • GSK Investigational Site

    Bialystok, 15-010, Poland

  • GSK Investigational Site

    Bydgoszcz, 85-079, Poland

  • GSK Investigational Site

    Bydgoszcz, 85-796, Poland

  • GSK Investigational Site

    Lodz, 90-141, Poland

  • GSK Investigational Site

    Lodz, 90-153, Poland

  • GSK Investigational Site

    Ostrowiec Świętokrzyski, 27-400, Poland

  • GSK Investigational Site

    Piaseczno, 05-500, Poland

  • GSK Investigational Site

    Rzeszów, 35-051, Poland

  • GSK Investigational Site

    Tarnów, 33-100, Poland

  • GSK Investigational Site

    Zawadzkie, 47-120, Poland

  • GSK Investigational Site

    Bloemfontein, 9301, South Africa

  • GSK Investigational Site

    Durban, 4001, South Africa

  • GSK Investigational Site

    Durban, 4093, South Africa

  • GSK Investigational Site

    George, 6529, South Africa

  • GSK Investigational Site

    Johannesburg, 1501, South Africa

  • GSK Investigational Site

    Johannesburg, 2001, South Africa

  • GSK Investigational Site

    Johannesburg, 2060, South Africa

  • GSK Investigational Site

    Pretoria, 0122, South Africa

  • GSK Investigational Site

    Somerset West, 7130, South Africa

  • GSK Investigational Site

    Alcobendas, 28100, Spain

  • GSK Investigational Site

    Badalona, 08916, Spain

  • GSK Investigational Site

    Barcelona, 08017, Spain

  • GSK Investigational Site

    Barcelona, 08025, Spain

  • GSK Investigational Site

    Barcelona, 08036, Spain

  • GSK Investigational Site

    Granada, 18014, Spain

  • GSK Investigational Site

    Madrid, 28006, Spain

  • GSK Investigational Site

    Madrid, 28007, Spain

  • GSK Investigational Site

    Málaga, 29004, Spain

  • GSK Investigational Site

    Málaga, 29010, Spain

  • GSK Investigational Site

    Pamplona, 31008, Spain

  • GSK Investigational Site

    Pozuelo de Alarcón, 28223, Spain

  • GSK Investigational Site

    Santiago de Compostela, 15706, Spain

  • GSK Investigational Site

    Istanbul, 34020, Turkey (Türkiye)

  • GSK Investigational Site

    Izmir, 35100, Turkey (Türkiye)

  • GSK Investigational Site

    Izmir, 35110, Turkey (Türkiye)

  • GSK Investigational Site

    Mersin, 33343, Turkey (Türkiye)

  • GSK Investigational Site

    Belfast, BT9 7AB, United Kingdom

  • GSK Investigational Site

    Bristol, BS374AX, United Kingdom

  • GSK Investigational Site

    Corby, NN17 2UR, United Kingdom

  • GSK Investigational Site

    Hayle, TR27 5DT, United Kingdom

  • GSK Investigational Site

    Hull, HU12 8JD, United Kingdom

  • GSK Investigational Site

    London, SW3 6HP, United Kingdom

  • GSK Investigational Site

    Northwood, HA6 2RN, United Kingdom

  • GSK Investigational Site

    Orpington, BR5 3QG, United Kingdom

  • GSK Investigational Site

    Shipley, BD18 3SA, United Kingdom

  • GSK Investigational Site

    Wishaw, ML2 0DP, United Kingdom

  • GSK Investigational Site

    Wythenshawe, M23 9LT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.